Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Medicines Agency

- PMLiVE

Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

- PMLiVE

MHRA approves Menarini Stemline’s Korserdu for advanced or metastatic breast cancer

More than 55,000 new cases of breast cancer are diagnosed each year in the UK

- PMLiVE

Bristol Myers Squibb to acquire radiopharmaceutical specialist RayzeBio for $4.1bn

The merger includes a candidate in phase 3 development for gastroenteropancreatic neuroendocrine tumours

- PMLiVE

MHRA launches new International Recognition Procedure to help bring medicines to UK patients

The agency will partner with regulators in several countries including the EU and US

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

ICR study predicts response to radium-233 treatment in prostate cancer bone metastases

The findings could help determine which patients would benefit from the treatment

- PMLiVE

AstraZeneca to acquire cell therapy specialist Gracell in deal worth up to $1.2bn

The transaction includes a clinical-stage candidate being evaluated as a treatment for multiple myeloma

- PMLiVE

GSK gains rights to Hansoh’s ADC candidate in deal worth more than $1.7bn

HS-20093 is being developed for a range of solid tumour types, including lung cancer

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

- PMLiVE

ICR study increases understanding of advanced breast cancer complication

Breast cancer leptomeningeal metastasis affects one in 20 people with metastatic cases

- PMLiVE

Merck and Owkin collaborate to develop AI-powered diagnostics for cancer

The companies aim to develop a pre-screening test to improve MSI-H testing for cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links